CTOs on the Move

Bionovo

www.bionovo.com

 
Bionovo is a Emeryville, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bionovo.com
  • 5858 Horton St Ste 375
    Emeryville, CA USA 94608
  • Phone: 510.601.2000

Executives

Name Title Contact Details

Similar Companies

WCG IRB

WCG is the world`s leading provider of solutions that measurably improve the quality and efficiency of clinical research. Comprised of two divisions, the industry`s first central IRB – WCG IRB – and first clinical services organization, WCG enables biopharmaceutical companies, CROs, and institutions to advance the delivery of new treatments and therapies to patients, while maintaining the highest standards of human participant protection.

Baxter Pharmaceutical Products

Baxter Pharmaceutical Products is a New Providence, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Proneuron Biotechnologies

Proneuron Biotechnologies is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mustang Bio

Mustang Bio, Inc., a subsidiary of Fortress Biotech, Inc., is a clinical‐stage biopharmaceutical company focused on the development and commercialization of novel cancer immunotherapy products designed to leverage the patient`s own immune system to eliminate cancer cells. Mustang aims to acquire rights to these technologies by licensing or otherwise acquiring an ownership interest, funding research and development, and out-licensing or bringing the technologies to market. Mustang has partnered with the City of Hope National Medical Center (“COH”) and Fred Hutchinson Cancer Research Center in the development of proprietary chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies across many cancers. Mustang`s lead programs are in Phase 1 clinical trials at COH: MB-101 for the treatment of brain cancer and MB-102 as a therapeutic agent in acute myeloid leukemia.

Vascular Therapies

Vascular Therapies, Inc., a privately-held late-stage biopharmaceutical company, is developing the Sirolimus-eluting collagen implant for local, perivascular drug delivery.